dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | O’Shaughnessy, Joyce |
dc.contributor.author | Cortés Castan, Javier |
dc.contributor.author | Twelves, Chris |
dc.contributor.author | Goldstein, Lori J. |
dc.contributor.author | Alexis, Karenza |
dc.contributor.author | Xie, Ran |
dc.date.accessioned | 2021-09-03T10:51:26Z |
dc.date.available | 2021-09-03T10:51:26Z |
dc.date.issued | 2020-07-08 |
dc.identifier.citation | O’Shaughnessy J, Cortes J, Twelves C, Goldstein LJ, Alexis K, Xie R, et al. Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. Sci Rep. 2020 Jul 8;10:11203. |
dc.identifier.issn | 2045-2322 |
dc.identifier.uri | https://hdl.handle.net/11351/6269 |
dc.description | Càncer de mama; Marcadors predictius; Pronòstic |
dc.description.sponsorship | This study was funded by Eisai Inc., Woodcliff Lake, NJ. Medical writing support was provided by Jeffrey Bratz, PhD, Oxford PharmaGenesis, Newtown, PA, USA, and was funded by Eisai Inc., Woodcliff Lake, NJ, USA. |
dc.language.iso | eng |
dc.publisher | Nature Research |
dc.relation.ispartofseries | Scientific Reports;10 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject | Metàstasi |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Neoplasm Metastasis |
dc.title | Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41598-020-66980-0 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | metástasis neoplásica |
dc.relation.publishversion | https://doi.org/10.1038/s41598-020-66980-0 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [O'Shaughnessy J] Baylor University Medical Center, Texas Oncology and US Oncology, Dallas, TX, USA. [Cortes J] IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Twelves C] Leeds Institute of Medical Research at St James’s and Leeds Teaching Hospitals Trust, Leeds, UK. [Goldstein LJ] Fox Chase Cancer Center, Philadelphia, PA, USA. [Alexis K, Xie R] Eisai Inc., Woodclif Lake, NJ, USA |
dc.identifier.pmid | 32641747 |
dc.identifier.wos | 000548300100011 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |